Medical Xpress Cediranib is a drug that inhibits a class of proteins called vascular endothelial growth factor receptors which regulate blood vessel formation. The drug , developed by AstraZeneca, Wilmington, Del., has been tested in clinical trials against other ... and more »
EurekAlert (press release) The kinetics of nanoparticle biodegradation is an important factor that can control how and where a drug is released, impacting treatment efficacy as well as potential toxicity to nontarget tissues from nanoparticle exposure. ... Through its ... and more »
Seeking Alpha Safeway already offers a solid dividend yield of nearly 3%, but that is only part of the story as dividend growth potential is another positive factor . Safeway has increased the dividend annually since 2005. At that time, the dividend was 5 cents per ...
Examiner.com The nuclear transcription factor c-Jun is preferentially expressed in basal-cell carcinoma and this DNAzyme targets JUN messenger RNA and has inhibited the growth of a range of tumours in mice. "We found that there was tumour shrinkage in the majority ... and more »
NBCNews.com Some research shows melatonin production at night can help suppress cellular processes involved in cancer growth . Light and ... The study did try to control for a variety of known health risks, like smoking, body mass index, and recent medical ... and more »
Medical Xpress The subsequent bone loss, which is caused by too much bone breakdown known as osteolysis, helps feed the tumor, because the bone is a depot of factors that promote tumor growth . Degraded bone releases these stored factors , and the tumor grows. and more »
The Japan Times TRENTON, NEW JERSEY – Pfizer Inc., in a first for the drug industry, said it will begin selling its popular erectile dysfunction pill Viagra directly t...
Seeking Alpha After Merck's 2013Q1 earnings report on May 1, 2013, Kenneth Frazier, CEO, acknowledged that patent expirations and negative economic factors were "even tougher" than anticipated, and the company adjusted 2013 EPS guidance downwards from $2.03-$2.26 to ... and more »
ModernHealthcare.com The economy, healthcare reimbursement, hospital management, drug pipelines and other factors influence spending, said Dr. Art Kellermann, the Pa...
Science Daily (press release) Cediranib is a drug that inhibits a class of proteins called vascular endothelial growth factor receptors which regulate blood vessel formation. The drug , developed by AstraZeneca, Wilmington, Del., has been tested in clinical trials against other ... and more »
